U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06985368) titled 'A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients' on May 14.
Brief Summary: The main purpose To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A18 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
A secondary purpose To preliminarily evaluate the anti-tumor efficacy of SIBP-A18. Evaluate the effect of SIBP-A18 injection on QT/QTc interval in participants with advanced solid tumors
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Malignancy
Intervention:
DRUG: SIBP-A18
SIBP-A18 formula...